Interest in Type 2 Diabetes Research Topics in PAR-13-054 "Dissemination and Implementation Research in Health (R21)" to support the Global Alliance for Chronic Diseases (GACD) Initiative

Notice Number: NOT-TW-14-003

Key Dates
Release Date: December 5, 2013

Related Announcements

Issued by
Fogarty International Center (FIC)
Office of Behavioral and Social Sciences Research (OBSSR)


The National Institutes of Health is a participant in the Global Alliance for Chronic Diseases (GACD) (, a collection of publicly funded research agencies that supports innovative research collaborations to address the prevention and treatment of chronic diseases in vulnerable populations.
GACD member organizations are currently soliciting applications on type 2 diabetes with a focus on improving the science around implementation of existing interventions (GACD Calls for Proposals).

The above listed components of the NIH invite interested researchers to submit applications in this area through the existing trans-NIH Initiative on Dissemination and Implementation Science (PAR-13-054). Applicants should identify the GACD initiative in their abstracts and cover. Of note, only applications received for the February 2014 due date will be considered responsive to this notice.

The particular interests of the ICs in this Notice are as follows:

FIC focuses on research and research training in low and middle income countries (LMICs) that advance global health. Under this GACD related activity, FIC is especially interested in R21 applications that advance implementation science to control type 2 diabetes in the most vulnerable populations, especially in Sub Saharan Africa. This includes applications that focus on HIV-affected populations.

OBSSR is interested in co-funding scientifically meritorious applications that align with the interests of the participating Institutes and Centers, and are also relevant to behavioral and social science research and OBSSR’s mission which can be found at:


Cristina Rabad n-Diehl, PhD, MPH
National Heart, Lung, and Blood Institute
Telephone: 301-496-3620